Lambe J, Risher H, Filippatou AG, et al. - Researchers undertook this observational study to determine how retinal atrophy in patients with relapsing-remitting multiple sclerosis (RRMS) could be impacted by rituximab. For this purpose, they conducted serial optical coherence tomography scans in a cohort consisting of patients with RRMS receiving rituximab and compared rates of ganglion cell + inner plexiform layer (GCIPL) atrophy to those noted in age- and gender-matched glatiramer acetate –and natalizumab-managed patients with RRMS as well as healthy controls (HCs). Findings revealed rituximab-induced modulation of retinal atrophy in RRMS. Post-12 months of rituximab therapy, there may happen greater attenuation of retinal atrophy, thereafter, GCIPL atrophy rates were identified to be similar to those noted in natalizumab-managed patients with RRMS and HCs. These data raise the possibility that the neuroprotective therapeutic response with rituximab in RRMS may take up to 12 months.